

Fax completed form to: 1-866-868-0858  
Questions, please call: 1-866-316-6049

**Important Information About Prescription Drug Coverage**

---

To: \_\_\_\_\_ From: \_\_\_\_\_

Fax: \_\_\_\_\_ Pages: \_\_\_\_\_

Re: Faslodex® (fulvestrant): Prior Authorization Request Form: Please respond.

---

- Please complete the attached Faslodex® (fulvestrant) Prior Authorization Request Form
- To expedite the review process please complete all requested fields.
- Completed forms should be faxed to: 1-866-868-0858. It is not necessary to fax this cover page.

**Please note:** By signing the attached form you are certifying that the treatment requested is medically necessary. No contraindications are present and precautions have been considered. You will be supervising the patient's treatment. Supporting documentation is available in the patient's record. Signature on this form attests to the fact that the corresponding ICD-9 code has been documented in the patients chart and submitted on a CMS- 1500 form.

**Information about this drug**

---

**Faslodex®(fulvestrant)**

In clinical trials Faslodex® has been found to be no more effective than tamoxifen or anastrozole (Arimidex®) in the treatment of advanced breast cancer in postmenopausal women.

You can make an expedited request by indicating this at the top of the attached form. If you request an expedited review, and sign the attached form, you certify that applying the 72 hour standard review time frame may seriously jeopardize the life or health of the member or the member's ability to regain maximum function.

**Information on the attached form is protected health information and subject to all privacy and security regulations under HIPAA.**

# Prior Authorization Request Form

Fax completed form to 1-866-868-0858 Need help? Call 1-866-316-6049

## Patient Information

Name \_\_\_\_\_  
Member ID \_\_\_\_\_  
Medicare ID \_\_\_\_\_  
Date of birth \_\_\_\_\_ Sex: M / F  
Address \_\_\_\_\_  
City \_\_\_\_\_  
State \_\_\_\_\_ ZIP \_\_\_\_\_  
Phone \_\_\_\_\_  
Nursing home resident? YES / NO  
Home care patient? YES / NO

## Prescriber and Pharmacy Information

Name \_\_\_\_\_  
Specialty \_\_\_\_\_  
DEA \_\_\_\_\_  
NPI \_\_\_\_\_  
Address \_\_\_\_\_  
City \_\_\_\_\_  
State \_\_\_\_\_ ZIP \_\_\_\_\_  
Phone \_\_\_\_\_ Fax \_\_\_\_\_  
Pharmacy name \_\_\_\_\_  
NCPDP \_\_\_\_\_  
NPI \_\_\_\_\_  
Phone \_\_\_\_\_ Fax \_\_\_\_\_

## All items below this line are for Physician Use Only

### Information for Requested Drug

Strength: \_\_\_\_\_ Dosage form: \_\_\_\_\_ Qty per 30 days: \_\_\_\_\_ Drug is (circle one): Newly prescribed/Refill  
Directions: \_\_\_\_\_ Diagnosis: \_\_\_\_\_ ICD-9 Code: \_\_\_\_\_

Standard Reviews will be completed in under 72 hours. An expedited review is available if you certify that a standard review timeframe will seriously jeopardize the health of your patient. To request an expedited review, simply indicate this at the top of this page.

### Faslodex®(fulvestrant) Criteria

- 1 Please indicate Faslodex®'s dispensing location:  
 the pharmacy  
 the physician's office incident to a physician's service  
 other
- 2 Is the prescribing physician an oncologist or has an oncologist been consulted?  
 Yes  No
- 3 Please specify indication for use:  
 Hormone receptor-positive breast cancer  
 Other: .....
- 4 Does patient have advanced breast cancer that has progressed during or recurred following antiestrogen therapy?  
 Yes  No
- 5 Has patient failed to receive a clinically appropriate therapeutic response OR demonstrated intolerance from 2 or more of the following therapies over a period of 30 or more days for each drug? (Check all that apply)  
 Yes  No  
 tamoxifen (Nolvadex®)  
 anastrozole (Arimidex®)  
 letrozole (Femara®)  
 exemestane (Aromasin®)  
 toremifene (Fareston®)

Medical justification: (Attach additional page if necessary): \_\_\_\_\_  
\_\_\_\_\_

Prescriber's signature: \_\_\_\_\_ Date: \_\_\_\_\_